Expert Interview
A second look at the current treatment landscape for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) and the potential of Zanubrutinib(BRUKINSA®) and the phase 3 ALPINE trial.
Ticker(s): BGNEInstitution: Wake Forest Baptist Medical Center
- Hematology Specialist at Wake Forest Baptist Medical Center
- Manages 15 patients with non-advanced systemic mastocytosis
- Prescribes and is comfortable discussing the literature to date on Aykavit
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
